{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006671","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.506015+00:00","generated_at":"2026-06-09T00:47:21.498534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE","bullets":["Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.","Cash, equivalents & investments $70.4M at Sep 30, down from $125.8M at Dec 31, 2022.","Closed $92M private placement in October 2023; projects cash runway through end of 2025.","FDA cleared IND for NASH THR-β agonist ALG-055009; Phase 2a startup underway.","Awarded $8.5M NIAID contract to advance coronavirus protease inhibitor ALG-097558."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006671","json":"https://secwatch.observer/filing/0001171843-23-006671.json","markdown":"https://secwatch.observer/filing/0001171843-23-006671.md","text":"https://secwatch.observer/filing/0001171843-23-006671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/0001171843-23-006671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/f8k_110223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:47:21.498534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce3a0bc21256f82896f8812b3dac6ac30b24595a","claim":"Aligos Therapeutics, Inc. reported the third quarter 2023 results: net income $18.0 million, EPS $(0.41).","evidence_excerpt":"Net losses for the three months ended September 30, 2023 were $18.0 million or basic and diluted net loss per common share of $(0.41)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/0001171843-23-006671-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2023"},{"label":"Net income","value":"$18.0 million"},{"label":"EPS","value":"$(0.41)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}